Radiotherapy for laryngeal cancers - Archive ouverte HAL
Article Dans Une Revue Cancer/Radiothérapie Année : 2022

Radiotherapy for laryngeal cancers

Y. Pointreau
  • Fonction : Auteur
P. Blanchard
  • Fonction : Auteur
C. Khampan
  • Fonction : Auteur
P. Giraud
  • Fonction : Auteur
M. Lapeyre
  • Fonction : Auteur
P. Maingon
  • Fonction : Auteur

Résumé

We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of laryngeal cancers. Intensity modulated radiotherapy is the standard of care radiotherapy for the management of laryngeal cancers. Early stage T1 or T2 tumours can be treated either by radiotherapy or conservative surgery. For tumours requiring total laryngectomy (T2 or T3), an organ preservation strategy by either induction chemotherapy followed by radiotherapy or chemoradiotherapy with cisplatin is recommended. For T4 tumours, a total laryngectomy followed by radiotherapy is recommended when feasible. Dose regimens for definitive and postoperative radiotherapy are detailed in this article, as well as the selection and delineation of tumour and lymph node target volumes.
Fichier non déposé

Dates et versions

hal-03889481 , version 1 (08-12-2022)

Identifiants

Citer

J. Biau, Y. Pointreau, P. Blanchard, C. Khampan, P. Giraud, et al.. Radiotherapy for laryngeal cancers. Cancer/Radiothérapie, 2022, 26 (1-2), pp.206-212. ⟨10.1016/j.canrad.2021.09.004⟩. ⟨hal-03889481⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

More